ivabradine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
bradycardic agents 3312 155974-00-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • corlanor
  • corlentor
  • ivabradine hydrochloride
  • ivabradine
  • coraxan
  • procoralan
  • ivabradine HCl
Ivabradine is a pure heart rate lowering agent, acting by selective and specific inhibition of the cardiac pacemaker If current that controls the spontaneous diastolic depolarisation in the sinus node and regulates heart rate. The cardiac effects are specific to the sinus node with no effect on intra-atrial, atrioventricular or intraventricular conduction times, nor on myocardial contractility or ventricular repolarisation.
  • Molecular weight: 468.59
  • Formula: C27H36N2O5
  • CLOGP: 3.07
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 0
  • TPSA: 60.47
  • ALOGS: -4.36
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.46 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.66 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 10.27 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.28 % Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 20, 2019 PMDA Ono Pharmaceutical Co., Ltd.
April 15, 2015 FDA AMGEN INC
Oct. 25, 2005 EMA Les Laboratoires Servier

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 429.73 18.43 487 8091 673975 62806469
Photopsia 153.64 18.43 46 8532 4463 63475981
Bradycardia 144.03 18.43 101 8477 73126 63407318
Drug interaction 136.41 18.43 161 8417 228970 63251474
Electrocardiogram QT prolonged 107.54 18.43 78 8500 59452 63420992
Torsade de pointes 104.90 18.43 46 8532 13305 63467139
Ischaemic stroke 86.03 18.43 44 8534 17913 63462531
Cardiac failure 85.70 18.43 81 8497 89061 63391383
Syncope 77.24 18.43 87 8491 117298 63363146
Palpitations 76.63 18.43 85 8493 112685 63367759
First trimester pregnancy 73.23 18.43 10 8568 8 63480436
Drug effective for unapproved indication 63.83 18.43 22 8556 3342 63477102
Chest pain 61.57 18.43 107 8471 215852 63264592
Cardiac failure chronic 57.98 18.43 22 8556 4396 63476048
Congestive cardiomyopathy 57.46 18.43 24 8554 6158 63474286
Dizziness 54.78 18.43 154 8424 429771 63050673
Ventricular fibrillation 53.73 18.43 28 8550 11839 63468605
Crush syndrome 53.55 18.43 10 8568 119 63480325
Myoglobin blood increased 50.75 18.43 15 8563 1390 63479054
Apallic syndrome 50.73 18.43 13 8565 708 63479736
Sinus bradycardia 48.38 18.43 28 8550 14523 63465921
Pain 48.24 18.43 20 8558 740608 62739836
Heart rate decreased 46.82 18.43 43 8535 45517 63434927
Ventricular tachycardia 44.99 18.43 30 8548 19949 63460495
Bundle branch block left 44.91 18.43 21 8557 7038 63473406
Language disorder 44.40 18.43 15 8563 2145 63478299
Acute kidney injury 43.39 18.43 104 8474 263311 63217133
Hypotension 42.10 18.43 105 8473 272499 63207945
Sensorimotor disorder 40.33 18.43 10 8568 476 63479968
Ejection fraction decreased 39.68 18.43 29 8549 22303 63458141
Dyspnoea 38.07 18.43 183 8395 661130 62819314
Pneumobilia 34.94 18.43 7 8571 123 63480321
Orthopnoea 31.90 18.43 16 8562 6245 63474199
Angioedema 30.56 18.43 35 8543 47930 63432514
Hyperparathyroidism secondary 29.41 18.43 10 8568 1457 63478987
Genital rash 29.31 18.43 8 8570 556 63479888
Heart rate increased 28.50 18.43 48 8530 94190 63386254
Shock haemorrhagic 27.58 18.43 17 8561 9878 63470566
Visual impairment 26.86 18.43 44 8534 84402 63396042
Cardiogenic shock 26.80 18.43 21 8557 17911 63462533
Tachycardia 26.64 18.43 53 8525 118103 63362341
Lactic acidosis 26.20 18.43 29 8549 38258 63442186
Anaemia folate deficiency 25.61 18.43 6 8572 224 63480220
Alopecia 25.57 18.43 7 8571 337529 63142915
Acute pulmonary oedema 25.27 18.43 15 8563 8143 63472301
Hyperphosphataemia 25.25 18.43 10 8568 2238 63478206
Mitral valve incompetence 25.16 18.43 21 8557 19573 63460871
Joint swelling 24.44 18.43 7 8571 327659 63152785
Gastric antral vascular ectasia 23.99 18.43 7 8571 620 63479824
Lordosis 23.77 18.43 6 8572 307 63480137
Second trimester pregnancy 23.73 18.43 3 8575 0 63480444
Third trimester pregnancy 23.73 18.43 3 8575 0 63480444
Gastrointestinal tract adenoma 23.32 18.43 6 8572 332 63480112
Bronchospasm 23.19 18.43 19 8559 17261 63463183
Tuberculosis of central nervous system 23.14 18.43 6 8572 342 63480102
Angina pectoris 22.71 18.43 24 8554 30054 63450390
Femoral neck fracture 22.13 18.43 14 8564 8509 63471935
Nasopharyngitis 21.81 18.43 4 8574 254253 63226191
Oliguria 21.29 18.43 14 8564 9087 63471357
Drug ineffective 20.97 18.43 72 8506 1044693 62435751
Metabolic acidosis 20.84 18.43 28 8550 45041 63435403
Lupus myocarditis 20.32 18.43 4 8574 64 63480380
Serotonin syndrome 20.10 18.43 22 8556 28660 63451784
Sinus arrest 19.58 18.43 8 8570 1941 63478503
Pneumonia fungal 19.48 18.43 11 8567 5444 63475000
Postural orthostatic tachycardia syndrome 19.03 18.43 7 8571 1282 63479162
Arthralgia 18.84 18.43 30 8548 569680 62910764
Osteochondrosis 18.58 18.43 7 8571 1370 63479074

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 313.05 19.95 231 9202 91017 34856481
Bradycardia 121.01 19.95 124 9309 75294 34872204
Computerised tomogram coronary artery abnormal 120.47 19.95 24 9409 193 34947305
Hypotension 116.04 19.95 211 9222 221438 34726060
Ischaemic cardiomyopathy 90.73 19.95 41 9392 6348 34941150
Photopsia 87.58 19.95 29 9404 1939 34945559
Cardiac failure chronic 82.54 19.95 41 9392 7838 34939660
Ventricular dysfunction 71.56 19.95 30 9403 3875 34943623
Dyspnoea at rest 65.47 19.95 28 9405 3800 34943698
Dyspnoea 61.98 19.95 232 9201 376550 34570948
Cardiomyopathy 58.33 19.95 43 9390 16765 34930733
Asthma-chronic obstructive pulmonary disease overlap syndrome 57.40 19.95 19 9414 1268 34946230
N-terminal prohormone brain natriuretic peptide increased 57.03 19.95 23 9410 2692 34944806
Sinus bradycardia 56.21 19.95 38 9395 12925 34934573
Oesophageal obstruction 55.58 19.95 15 9418 493 34947005
Torsade de pointes 54.06 19.95 30 9403 7179 34940319
Bronchial hyperreactivity 52.13 19.95 19 9414 1690 34945808
Pulmonary oedema 51.84 19.95 64 9369 47465 34900033
Oedema peripheral 51.30 19.95 105 9328 119707 34827791
Left ventricular enlargement 50.78 19.95 15 9418 687 34946811
Ventricular arrhythmia 49.84 19.95 26 9407 5502 34941996
Presyncope 49.33 19.95 41 9392 19018 34928480
Ventricular extrasystoles 49.21 19.95 34 9399 11974 34935524
Ejection fraction decreased 49.15 19.95 41 9392 19113 34928385
Venous pressure jugular increased 48.83 19.95 15 9418 786 34946712
Bezoar 47.31 19.95 16 9417 1141 34946357
Blood pressure systolic decreased 45.88 19.95 23 9410 4480 34943018
Electrocardiogram abnormal 44.67 19.95 29 9404 9218 34938280
Pulmonary function test abnormal 44.33 19.95 19 9414 2591 34944907
Base excess decreased 41.24 19.95 10 9423 212 34947286
Glomerular filtration rate decreased 40.18 19.95 31 9402 12930 34934568
Hyperkalaemia 39.85 19.95 69 9364 69320 34878178
Drug interaction 38.52 19.95 141 9292 225805 34721693
Ventricular tachycardia 37.71 19.95 41 9392 26538 34920960
Dyspnoea exertional 37.43 19.95 52 9381 43227 34904271
Venous pressure jugular decreased 37.21 19.95 7 9426 40 34947458
Breath sounds abnormal 36.76 19.95 23 9410 6858 34940640
Blood potassium increased 35.61 19.95 32 9401 16463 34931035
Product prescribing error 35.41 19.95 37 9396 22890 34924608
Oxygen consumption decreased 34.73 19.95 9 9424 252 34947246
Eosinophilia 34.70 19.95 39 9394 26183 34921315
Atrial tachycardia 32.44 19.95 17 9416 3628 34943870
Urticaria chronic 32.22 19.95 7 9426 89 34947409
Angina pectoris 32.21 19.95 41 9392 31322 34916176
Dermatitis exfoliative generalised 32.17 19.95 17 9416 3690 34943808
Brain natriuretic peptide increased 30.44 19.95 19 9414 5640 34941858
Bronchial wall thickening 30.15 19.95 12 9421 1356 34946142
Tricuspid valve incompetence 29.50 19.95 23 9410 9737 34937761
Blood creatinine increased 29.16 19.95 73 9360 94903 34852595
Oculogyric crisis 28.44 19.95 12 9421 1574 34945924
Syncope 27.77 19.95 70 9363 91381 34856117
Eye movement disorder 27.76 19.95 16 9417 4111 34943387
Sinus arrest 27.37 19.95 12 9421 1728 34945770
Palpitations 27.30 19.95 43 9390 39943 34907555
ECG signs of myocardial ischaemia 27.22 19.95 7 9426 190 34947308
Death 27.16 19.95 41 9392 398008 34549490
Acute kidney injury 27.00 19.95 157 9276 304831 34642667
Ventricular enlargement 26.43 19.95 9 9424 655 34946843
Hypertrophy 25.44 19.95 8 9425 453 34947045
Non-compaction cardiomyopathy 25.23 19.95 5 9428 39 34947459
Left ventricular dilatation 25.16 19.95 9 9424 758 34946740
Tracheal atresia 24.48 19.95 4 9429 8 34947490
Status epilepticus 22.48 19.95 22 9411 12592 34934906
Body mass index increased 22.21 19.95 9 9424 1066 34946432
Left ventricular hypertrophy 22.09 19.95 18 9415 8112 34939386
Supraventricular extrasystoles 22.01 19.95 13 9420 3495 34944003
Cardiac failure acute 21.82 19.95 20 9413 10550 34936948
Acute myocardial infarction 21.67 19.95 46 9387 53673 34893825
Blood chloride increased 21.62 19.95 12 9421 2869 34944629
Cardiac ventricular thrombosis 21.55 19.95 9 9424 1151 34946347
Fluid retention 21.31 19.95 31 9402 26856 34920642
Mean cell haemoglobin decreased 21.25 19.95 10 9423 1696 34945802
Blood luteinising hormone increased 21.24 19.95 5 9428 93 34947405
Mitral valve incompetence 21.10 19.95 23 9410 14920 34932578
Concomitant disease aggravated 20.71 19.95 15 9418 5686 34941812
Oesophageal haemorrhage 20.44 19.95 9 9424 1309 34946189
Lichenoid keratosis 20.35 19.95 11 9422 2497 34945001

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 370.91 16.63 288 16704 154554 79572842
Off label use 316.96 16.63 633 16359 906582 78820814
Bradycardia 238.45 16.63 211 16781 135346 79592050
Photopsia 175.24 16.63 59 16933 5277 79722119
Drug interaction 153.68 16.63 298 16694 414885 79312511
Torsade de pointes 149.89 16.63 76 16916 19236 79708160
Hypotension 136.81 16.63 294 16698 440023 79287373
Cardiac failure chronic 136.29 16.63 60 16932 11075 79716321
Computerised tomogram coronary artery abnormal 126.00 16.63 24 16968 194 79727202
Ischaemic cardiomyopathy 95.90 16.63 42 16950 7653 79719743
Syncope 88.19 16.63 146 16846 179303 79548093
Sinus bradycardia 87.76 16.63 59 16933 25188 79702208
Dyspnoea 87.52 16.63 387 16605 856638 78870758
Ventricular tachycardia 83.14 16.63 70 16922 41865 79685531
Palpitations 80.41 16.63 116 16876 126494 79600902
Ejection fraction decreased 79.66 16.63 63 16929 34514 79692882
Electrocardiogram QT prolonged 79.26 16.63 97 16895 90289 79637107
Acute kidney injury 71.68 16.63 258 16734 519146 79208250
Ischaemic stroke 69.19 16.63 57 16935 33074 79694322
First trimester pregnancy 63.78 16.63 9 16983 4 79727392
Ventricular extrasystoles 63.62 16.63 44 16948 19660 79707736
Pain 62.98 16.63 36 16956 703766 79023630
Ventricular dysfunction 62.72 16.63 29 16963 5994 79721402
N-terminal prohormone brain natriuretic peptide increased 62.67 16.63 27 16965 4728 79722668
Left ventricular enlargement 62.60 16.63 17 16975 729 79726667
Chest pain 59.95 16.63 163 16829 282141 79445255
Ventricular fibrillation 58.60 16.63 51 16941 31875 79695521
Ventricular arrhythmia 57.73 16.63 31 16961 8809 79718587
Congestive cardiomyopathy 57.15 16.63 34 16958 11746 79715650
Presyncope 56.78 16.63 56 16936 40998 79686398
Dizziness 56.75 16.63 242 16750 526199 79201197
Angina pectoris 56.18 16.63 62 16930 51670 79675726
Bronchial hyperreactivity 52.71 16.63 21 16971 3019 79724377
Dyspnoea at rest 51.63 16.63 27 16965 7275 79720121
Cardiomyopathy 50.87 16.63 45 16947 28729 79698667
Hyperkalaemia 49.46 16.63 88 16904 114310 79613086
Glomerular filtration rate decreased 49.37 16.63 40 16952 22662 79704734
Oesophageal obstruction 48.65 16.63 15 16977 1011 79726385
ECG signs of myocardial ischaemia 48.52 16.63 12 16980 354 79727042
Asthma-chronic obstructive pulmonary disease overlap syndrome 48.14 16.63 20 16972 3201 79724195
Atrial tachycardia 46.54 16.63 25 16967 7108 79720288
Mitral valve incompetence 45.25 16.63 42 16950 28523 79698873
Bundle branch block left 45.10 16.63 29 16963 11484 79715912
Drug effective for unapproved indication 44.76 16.63 23 16969 5978 79721418
Crush syndrome 44.24 16.63 10 16982 198 79727198
Pulmonary function test abnormal 43.30 16.63 20 16972 4124 79723272
Eosinophilia 41.90 16.63 50 16942 45295 79682101
Oedema peripheral 41.42 16.63 133 16859 252155 79475241
Apallic syndrome 41.08 16.63 13 16979 955 79726441
Venous pressure jugular increased 40.79 16.63 14 16978 1326 79726070
Dyspnoea exertional 40.26 16.63 69 16923 87004 79640392
Tricuspid valve incompetence 39.25 16.63 33 16959 19679 79707717
Base excess decreased 38.09 16.63 10 16982 376 79727020
Bezoar 37.86 16.63 16 16976 2672 79724724
Blood pressure systolic decreased 36.38 16.63 25 16967 11051 79716345
Pulmonary oedema 35.74 16.63 66 16926 88188 79639208
Venous pressure jugular decreased 34.24 16.63 7 16985 84 79727312
Brain natriuretic peptide increased 33.83 16.63 22 16970 8878 79718518
Blood potassium increased 33.37 16.63 36 16956 29239 79698157
Sinus arrest 33.29 16.63 16 16976 3606 79723790
Blood creatinine increased 32.33 16.63 89 16903 154968 79572428
Body mass index increased 32.29 16.63 13 16979 1920 79725476
Myoglobin blood increased 32.27 16.63 15 16977 3136 79724260
Language disorder 31.99 16.63 15 16977 3199 79724197
Oxygen consumption decreased 31.78 16.63 9 16983 451 79726945
Orthopnoea 31.36 16.63 22 16970 10051 79717345
Electrocardiogram abnormal 31.24 16.63 27 16965 16710 79710686
Nasopharyngitis 30.87 16.63 8 16984 253873 79473523
Rheumatoid arthritis 30.84 16.63 4 16988 208466 79518930
Dermatitis exfoliative generalised 30.26 16.63 19 16973 7222 79720174
Joint swelling 29.97 16.63 12 16980 288634 79438762
Sensorimotor disorder 29.80 16.63 10 16982 884 79726512
Product prescribing error 29.79 16.63 42 16950 44771 79682625
Arthralgia 29.29 16.63 48 16944 571755 79155641
Acute pulmonary oedema 28.70 16.63 24 16968 14206 79713190
Alopecia 28.69 16.63 7 16985 231348 79496048
Infusion related reaction 28.48 16.63 7 16985 230230 79497166
Cardiac failure acute 28.38 16.63 27 16965 18902 79708494
Ventricular enlargement 27.66 16.63 9 16983 723 79726673
Pneumobilia 27.52 16.63 7 16985 232 79727164
Non-compaction cardiomyopathy 26.41 16.63 5 16987 39 79727357
Breath sounds abnormal 26.28 16.63 24 16968 15960 79711436
Hepatic enzyme increased 25.85 16.63 4 16988 182606 79544790
Diastolic dysfunction 25.54 16.63 20 16972 10791 79716605
Osteochondrosis 25.21 16.63 11 16981 1985 79725411
Urticaria chronic 25.14 16.63 8 16984 598 79726798
Blood pressure decreased 24.73 16.63 61 16931 99405 79627991
Vertigo 24.68 16.63 49 16943 69033 79658363
Low cardiac output syndrome 24.52 16.63 9 16983 1036 79726360
Musculoskeletal stiffness 24.39 16.63 4 16988 175004 79552392
Sinusitis 24.07 16.63 6 16986 195495 79531901
Lactic acidosis 24.06 16.63 49 16943 70310 79657086
Dyspnoea paroxysmal nocturnal 24.05 16.63 11 16981 2217 79725179
Oculogyric crisis 24.02 16.63 12 16980 2940 79724456
Abdominal discomfort 23.56 16.63 12 16980 250715 79476681
Cardiac ventricular thrombosis 23.14 16.63 10 16982 1763 79725633
Heart rate decreased 22.90 16.63 48 16944 70268 79657128
Hypertrophy 22.86 16.63 8 16984 802 79726594
Completed suicide 22.74 16.63 12 16980 245755 79481641
Mean cell haemoglobin decreased 22.72 16.63 15 16977 6209 79721187
Arthropathy 22.66 16.63 5 16987 177106 79550290
Second trimester pregnancy 22.36 16.63 3 16989 0 79727396
Third trimester pregnancy 22.36 16.63 3 16989 0 79727396
Bronchial wall thickening 22.27 16.63 11 16981 2630 79724766
Acute myocardial infarction 22.14 16.63 50 16942 76986 79650410
Infection 22.07 16.63 12 16980 241700 79485696
Exercise tolerance decreased 21.90 16.63 17 16975 9054 79718342
Eye movement disorder 21.52 16.63 16 16976 7995 79719401
Supraventricular extrasystoles 21.15 16.63 15 16977 6972 79720424
Anaemia folate deficiency 21.14 16.63 6 16986 303 79727093
Genital rash 21.00 16.63 8 16984 1020 79726376
Left ventricular hypertrophy 20.78 16.63 18 16974 11173 79716223
Acute coronary syndrome 20.67 16.63 24 16968 21109 79706287
Arrhythmia 20.16 16.63 42 16950 61230 79666166
Oesophageal haemorrhage 19.95 16.63 9 16983 1758 79725638
Haematoma 19.83 16.63 38 16954 52157 79675239
Conduction disorder 19.71 16.63 11 16981 3368 79724028
Muscular weakness 19.65 16.63 5 16987 160724 79566672
Rash 19.45 16.63 61 16931 578297 79149099
Feeling abnormal 19.28 16.63 76 16916 159123 79568273
Hyperparathyroidism secondary 19.27 16.63 10 16982 2650 79724746
International normalised ratio decreased 19.21 16.63 15 16977 8055 79719341
Kyphosis 19.16 16.63 10 16982 2681 79724715
Cardiogenic shock 19.08 16.63 33 16959 41881 79685515
Left ventricular dysfunction 18.96 16.63 22 16970 19339 79708057
Lordosis 18.90 16.63 6 16986 445 79726951
Blood luteinising hormone increased 18.60 16.63 5 16987 206 79727190
Tuberculosis of central nervous system 18.38 16.63 6 16986 487 79726909
Shock haemorrhagic 18.33 16.63 22 16970 20038 79707358
Gastrointestinal tract adenoma 18.28 16.63 6 16986 495 79726901
Cardiac disorder 18.14 16.63 42 16950 65715 79661681
Wrong technique in product usage process 18.03 16.63 45 16947 73830 79653566
Gastric antral vascular ectasia 17.95 16.63 7 16985 951 79726445
Sudden death 17.86 16.63 23 16969 22488 79704908
Blood chloride increased 17.79 16.63 12 16980 5144 79722252
Febrile neutropenia 17.66 16.63 14 16978 230985 79496411
Circulatory collapse 17.60 16.63 30 16962 37638 79689758
Intentional overdose 17.48 16.63 56 16936 105904 79621492
Drug hypersensitivity 17.32 16.63 23 16969 298893 79428503
Lupus myocarditis 17.17 16.63 4 16988 91 79727305

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01EB17 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
OTHER CARDIAC PREPARATIONS
Other cardiac preparations
ATC C07FX05 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents, other combinations
ATC C07FX06 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents, other combinations
MeSH PA D002317 Cardiovascular Agents
FDA EPC N0000191544 Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker
FDA MoA N0000191546 Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists
CHEBI has role CHEBI:38147 cardiotonic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic heart failure indication 48447003
Angina pectoris indication 194828000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.45 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 5MG BASE CORLANOR AMGEN INC N206143 April 15, 2015 RX TABLET ORAL 7361649 Feb. 22, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
EQ 5MG BASE CORLANOR AMGEN INC N206143 April 15, 2015 RX TABLET ORAL 7361650 Feb. 22, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
EQ 5MG BASE CORLANOR AMGEN INC N206143 April 15, 2015 RX TABLET ORAL 7879842 Feb. 22, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
EQ 7.5MG BASE CORLANOR AMGEN INC N206143 April 15, 2015 RX TABLET ORAL 7361649 Feb. 22, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
EQ 7.5MG BASE CORLANOR AMGEN INC N206143 April 15, 2015 RX TABLET ORAL 7361650 Feb. 22, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
EQ 7.5MG BASE CORLANOR AMGEN INC N206143 April 15, 2015 RX TABLET ORAL 7879842 Feb. 22, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
5MG/5ML (1MG/ML) CORLANOR AMGEN INC N209964 April 22, 2019 RX SOLUTION ORAL 7361649 Feb. 22, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
5MG/5ML (1MG/ML) CORLANOR AMGEN INC N209964 April 22, 2019 RX SOLUTION ORAL 7361650 Feb. 22, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
5MG/5ML (1MG/ML) CORLANOR AMGEN INC N209964 April 22, 2019 RX SOLUTION ORAL 7879842 Feb. 22, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
EQ 5MG BASE CORLANOR AMGEN INC N206143 April 15, 2015 RX TABLET ORAL 7867996 Dec. 12, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
EQ 7.5MG BASE CORLANOR AMGEN INC N206143 April 15, 2015 RX TABLET ORAL 7867996 Dec. 12, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
5MG/5ML (1MG/ML) CORLANOR AMGEN INC N209964 April 22, 2019 RX SOLUTION ORAL 7867996 Dec. 12, 2026 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5MG/5ML (1MG/ML) CORLANOR AMGEN INC N209964 April 22, 2019 RX SOLUTION ORAL April 22, 2026 INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE
5MG/5ML (1MG/ML) CORLANOR AMGEN INC N209964 April 22, 2019 RX SOLUTION ORAL Oct. 22, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Ion channel BLOCKER IC50 5.70 IUPHAR DRUG LABEL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Ion channel BLOCKER UNKNOWN DRUG LABEL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3 Ion channel BLOCKER IC50 5.70 IUPHAR DRUG LABEL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel EC50 5.37 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Ion channel EC50 5.35 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Ion channel EC50 5.34 CHEMBL

External reference:

IDSource
D07165 KEGG_DRUG
148849-67-6 SECONDARY_CAS_RN
4034416 VANDF
C0257190 UMLSCUI
CHEBI:85969 CHEBI
CHEMBL471737 ChEMBL_ID
CHEMBL2145077 ChEMBL_ID
D000077550 MESH_DESCRIPTOR_UI
DB09083 DRUGBANK_ID
2357 IUPHAR_LIGAND_ID
7523 INN_ID
3H48L0LPZQ UNII
132999 PUBCHEM_CID
1649479 RXNORM
20884 MMSL
233849 MMSL
d05706 MMSL
011156 NDDF
011157 NDDF
420906000 SNOMEDCT_US
421228002 SNOMEDCT_US
421692002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 55513-800 TABLET, FILM COATED 5 mg ORAL NDA 31 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 55513-800 TABLET, FILM COATED 5 mg ORAL NDA 31 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 55513-800 TABLET, FILM COATED 5 mg ORAL NDA 31 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 55513-810 TABLET, FILM COATED 7.50 mg ORAL NDA 31 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 55513-810 TABLET, FILM COATED 7.50 mg ORAL NDA 31 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 55513-810 TABLET, FILM COATED 7.50 mg ORAL NDA 31 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 55513-813 SOLUTION 5 mg ORAL NDA 31 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 55513-813 SOLUTION 5 mg ORAL NDA 31 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 55513-813 SOLUTION 5 mg ORAL NDA 31 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 70518-3309 TABLET, FILM COATED 5 mg ORAL NDA 33 sections
Corlanor HUMAN PRESCRIPTION DRUG LABEL 1 70518-3309 TABLET, FILM COATED 5 mg ORAL NDA 33 sections